Distribution of genital human papillomavirus (HPV) genotypes in Croatian women with cervical intraepithelial neoplasia (CIN)--a pilot study. 2013

Ivana Roksandić-Krizan, and Zinka Bosnjak, and Magdalena Perić, and Ivona Durkin, and Vlasta Zujić Atalić, and Dubravka Vuković
Institute for Public Health for Osijek-Baranja County, Department of Microbiology, Osijek, Croatia.

Genital infection with high-risk human papillomavirus (HR HPV) associates with increased risk of developing precancerous lesions, such as cervical intraepithelial neoplasia (CIN). The objective of this pilot study conducted in north-east Croatia was to determine the prevalence of HPV genital infection in women with abnormal cervical cytology and to determine its association with their age and HPV genotype(s). From March 2009 to December 2011, cervical swabs from 100 women were analysed for HR HPV infection (AMPLICOR HPV Test, Roche Diagnostics) and genotyped for high risk (HR), intermediate (IR) and low risk (LR) HPVs (Linear Array HPV Genotyping Test, Roche Diagnostics). The most prevalent HR genotypes in women with CIN were HPV 16 (27.6%), HPV 31 (11.8%), HPV 51 and HPV 52 (10.2% each). The most prevalent IR genotypes were HPV 66 (30%) and HPV 62 (23.3%). The most prevalent LR genotype was HPV 6 (20.3%). Women between 21 and 25 years of age showed the highest rate of HPV infection (44.2%). Moreover, women younger than 35 years showed a significant association (p < 0.01) and positive correlation (r = 0.67; p < 0.05) between HR HPV infection and CIN stages 1 and 2. Multiple HPV infections were found in almost half of the women. This is the first study that analysed the prevalence of genital infection with HR/IR/LR HPVs in women with CIN from north-east Croatia. Despite the preliminary nature of this pilot study, the lower prevalence of some HR HPVs (HPV18) and the higher prevalence of other HR HPVs (HPVs 51, 52 and 31) may imply the necessity for the development of more targeted anti-HPV vaccines or other strategies for more efficient protection against oncogenic HPV infection in women from our region.

UI MeSH Term Description Entries
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D002578 Uterine Cervical Dysplasia Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE. Cervical Dysplasia,Cervical Intraepithelial Neoplasia,Cervix Dysplasia,Dysplasia of Cervix Uteri,Neoplasia, Cervical Intraepithelial,Cervical Intraepithelial Neoplasia, Grade III,Cervical Intraepithelial Neoplasms,Intraepithelial Neoplasia, Cervical,Cervical Dysplasia, Uterine,Cervical Dysplasias,Cervical Intraepithelial Neoplasm,Cervix Uteri Dysplasia,Cervix Uteri Dysplasias,Dysplasia, Cervical,Dysplasia, Cervix,Dysplasia, Uterine Cervical,Intraepithelial Neoplasm, Cervical,Intraepithelial Neoplasms, Cervical,Neoplasm, Cervical Intraepithelial,Neoplasms, Cervical Intraepithelial
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D052685 Alphapapillomavirus A genus of DNA viruses in the family PAPILLOMAVIRIDAE. They preferentially infect the anogenital and ORAL MUCOSA in humans and primates, causing both malignant and benign neoplasms. Cutaneous lesions are also seen. Alphapapillomaviruses
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults

Related Publications

Ivana Roksandić-Krizan, and Zinka Bosnjak, and Magdalena Perić, and Ivona Durkin, and Vlasta Zujić Atalić, and Dubravka Vuković
January 1997, Minerva ginecologica,
Ivana Roksandić-Krizan, and Zinka Bosnjak, and Magdalena Perić, and Ivona Durkin, and Vlasta Zujić Atalić, and Dubravka Vuković
June 2009, Acta dermatovenerologica Alpina, Pannonica, et Adriatica,
Ivana Roksandić-Krizan, and Zinka Bosnjak, and Magdalena Perić, and Ivona Durkin, and Vlasta Zujić Atalić, and Dubravka Vuković
January 1993, Archives of gynecology and obstetrics,
Ivana Roksandić-Krizan, and Zinka Bosnjak, and Magdalena Perić, and Ivona Durkin, and Vlasta Zujić Atalić, and Dubravka Vuković
November 2009, Gynecologic oncology,
Ivana Roksandić-Krizan, and Zinka Bosnjak, and Magdalena Perić, and Ivona Durkin, and Vlasta Zujić Atalić, and Dubravka Vuković
November 1988, Cancer,
Ivana Roksandić-Krizan, and Zinka Bosnjak, and Magdalena Perić, and Ivona Durkin, and Vlasta Zujić Atalić, and Dubravka Vuković
June 2011, Gynecologic oncology,
Ivana Roksandić-Krizan, and Zinka Bosnjak, and Magdalena Perić, and Ivona Durkin, and Vlasta Zujić Atalić, and Dubravka Vuković
March 2013, The Indian journal of medical research,
Ivana Roksandić-Krizan, and Zinka Bosnjak, and Magdalena Perić, and Ivona Durkin, and Vlasta Zujić Atalić, and Dubravka Vuković
February 2015, BMC systems biology,
Ivana Roksandić-Krizan, and Zinka Bosnjak, and Magdalena Perić, and Ivona Durkin, and Vlasta Zujić Atalić, and Dubravka Vuković
January 2003, European journal of gynaecological oncology,
Ivana Roksandić-Krizan, and Zinka Bosnjak, and Magdalena Perić, and Ivona Durkin, and Vlasta Zujić Atalić, and Dubravka Vuković
February 2019, BMC infectious diseases,
Copied contents to your clipboard!